NZ595492A - Improved Process for the Preparation of Lenalidomide - Google Patents

Improved Process for the Preparation of Lenalidomide

Info

Publication number
NZ595492A
NZ595492A NZ595492A NZ59549210A NZ595492A NZ 595492 A NZ595492 A NZ 595492A NZ 595492 A NZ595492 A NZ 595492A NZ 59549210 A NZ59549210 A NZ 59549210A NZ 595492 A NZ595492 A NZ 595492A
Authority
NZ
New Zealand
Prior art keywords
lenalidomide
isoindol
dione
piperidine
dihydro
Prior art date
Application number
NZ595492A
Other languages
English (en)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Suresh Hasbe
Shreyas Bhandari
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of NZ595492A publication Critical patent/NZ595492A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Glass Compositions (AREA)
NZ595492A 2009-03-02 2010-03-01 Improved Process for the Preparation of Lenalidomide NZ595492A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
NZ595492A true NZ595492A (en) 2013-07-26

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595492A NZ595492A (en) 2009-03-02 2010-03-01 Improved Process for the Preparation of Lenalidomide

Country Status (16)

Country Link
US (1) US8946265B2 (enExample)
EP (1) EP2403845B1 (enExample)
JP (1) JP5727944B2 (enExample)
CN (1) CN102414196A (enExample)
AU (1) AU2010220204B2 (enExample)
CA (1) CA2753241C (enExample)
CY (1) CY1115376T1 (enExample)
DK (1) DK2403845T3 (enExample)
ES (1) ES2487215T3 (enExample)
HR (1) HRP20140686T1 (enExample)
NZ (1) NZ595492A (enExample)
PL (1) PL2403845T3 (enExample)
PT (1) PT2403845E (enExample)
SI (1) SI2403845T1 (enExample)
SM (1) SMT201400100B (enExample)
WO (1) WO2010100476A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
EP2545043B1 (en) 2010-03-08 2019-04-24 Natco Pharma Limited Anhydrous lenalidomide form-i
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
CA2842316A1 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)­piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
WO2014164299A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EP3308835B1 (en) 2013-03-13 2020-01-01 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN105263579B (zh) 2013-03-13 2020-01-10 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗血管炎中的用途
WO2014160686A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
EP3137450A2 (en) * 2014-04-26 2017-03-08 Shilpa Medicare Limited Crystalline lenalidomide process
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
MX369968B (es) * 2014-08-19 2019-11-27 Synthon Bv Procedimiento para elaborar la forma cristalina a de lenalidomida.
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2017109041A1 (en) * 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
JP2020535192A (ja) * 2017-09-27 2020-12-03 バイオコン・リミテッド レナリドミドの結晶形
WO2019138424A1 (en) * 2018-01-11 2019-07-18 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体（上海）有限公司 一种制备来那度胺的方法
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
ES2438725T3 (es) 2004-09-03 2014-01-20 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
US8304250B2 (en) 2007-04-16 2012-11-06 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
WO2009077784A2 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited Hpcl method for analysing clopidogrel
CA2717326C (en) 2008-03-11 2018-10-23 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
CN102272118A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
SI2403845T1 (sl) 2014-09-30
EP2403845B1 (en) 2014-04-30
US20120071509A1 (en) 2012-03-22
CA2753241C (en) 2015-06-16
US8946265B2 (en) 2015-02-03
DK2403845T3 (da) 2014-08-04
CY1115376T1 (el) 2017-01-04
SMT201400100B (it) 2014-11-10
WO2010100476A3 (en) 2011-06-16
WO2010100476A2 (en) 2010-09-10
AU2010220204B2 (en) 2015-10-08
JP5727944B2 (ja) 2015-06-03
AU2010220204A1 (en) 2011-10-20
HRP20140686T1 (hr) 2014-09-26
CN102414196A (zh) 2012-04-11
CA2753241A1 (en) 2010-09-10
EP2403845A2 (en) 2012-01-11
PL2403845T3 (pl) 2014-09-30
PT2403845E (pt) 2014-08-04
JP2012519207A (ja) 2012-08-23
ES2487215T3 (es) 2014-08-20

Similar Documents

Publication Publication Date Title
NZ595492A (en) Improved Process for the Preparation of Lenalidomide
UA94062C2 (en) Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
IL196885A0 (en) Use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
PH12012502512A1 (en) 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors
LTPA2017015I1 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
ZA202007564B (en) Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
MY161880A (en) Compositions and methods for treating colitis
MX2020003585A (es) Formulaciones de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipi ridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il )pirazolo[1,5-a]piridina-3-carbonitrilo.
NZ728392A (en) High dosage strength tablets of rucaparib
MX2017002875A (es) Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
EA201270616A1 (ru) Ингибиторы вируса гепатита с
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
WO2013023015A3 (en) Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
EP2477975A4 (en) SOLID FORMS OF 3- (4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL) -PIPERIDINE-2,6-DION AND METHOD OF MANUFACTURING THEREOF
MX2023010897A (es) Antagonista del receptor de melanocortina subtipo 2 (mc2r) para el tratamiento de enfermedades.
ZA202409847B (en) Gastro-resistant controlled release oral dosage forms
MX2010004017A (es) 5-cianotienopiridinas para el tratamiento de tumores.
SG10201909188XA (en) Novel therapies for cancer
IL304617A (en) Inductive heating arrangement for heating spray-forming substrates
WO2010079063A3 (en) Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2010117756A3 (en) Substituted benzimidazole pharmaceutical formulations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAR 2017 BY DENNEMEYER SA

Effective date: 20140214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2018 BY RENEWALS TEAM

Effective date: 20170325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2019 BY RENEWALS TEAM

Effective date: 20180210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2020 BY RENEWALS TEAM

Effective date: 20190105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY RENEWALS TEAM

Effective date: 20200224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY IPAN GMBH

Effective date: 20210218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2023 BY IPAN GMBH

Effective date: 20220215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2024 BY IPAN GMBH

Effective date: 20230215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2025 BY IPAN GMBH

Effective date: 20240216

ASS Change of ownership

Owner name: TIANISH LABORATORIES PRIVATE LIMITED, IN

Effective date: 20250417

LAPS Patent lapsed